Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243594 | 0.85 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL13738818 | 0.84 | PRMT5 (0.40) | DGAT1 | |
| SCHEMBL18547536 | 0.84 | DGAT1 (0.40) | DGAT1NPC1 | |
| SCHEMBL29407693 | 0.84 | PRMT5 (0.40) | DGAT1 | |
| SCHEMBL127257 | 0.84 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL1396237 | 0.84 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12 | |
| SCHEMBL18593997 | 0.83 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12MEN1NR2F2 | |
| SCHEMBL20893945 | 0.83 | ALDH1A1 (0.36) | DGAT1KCNH2SCN5ASCN9A | |
| SCHEMBL18583995 | 0.83 | FGFR1 (0.35) | FGFR1FGFR4SLC22A12MEN1NR2F2 | |
| SCHEMBL1291499 | 0.82 | HDAC1 (0.38) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747250-A1 | KINASE INHIBITORS | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250353857-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1 R) | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2025-11-20 | — | — | US | disclosed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025019585-A1 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240376102-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | NATCO PHARMA LIMITED (IN) | 2024-11-14 | — | — | US | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1773826-A4 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| CN-101432287-A | Pyrrolopyrimidine derivatives as HSP90 inhibitors | VERNALIS R&D LTD (GB) | 2009-05-13 | — | — | CN | disclosed |
| EP-2007767-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R&D) LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| EP-1773826-A2 | C-MET MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | FGFR1 1535/4885FGFR4 1065/4885DGAT1 3451/4885 |
| US-20250353857-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1 R) | CSF1R, CSF3R, IL1RN | FGFR1 112/4885FGFR4 701/4885DGAT1 4132/4885 |
| US-20240376102-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | JAK1, JAK2, FLT3 | FGFR1 102/4885FGFR4 51/4885DGAT1 4670/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | FGFR1 705/4885FGFR4 544/4885DGAT1 3393/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | FGFR1 567/4885FGFR4 744/4885DGAT1 3810/4885 |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | FGFR1 157/4885FGFR4 1088/4885DGAT1 4262/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | FGFR1 4312/4885FGFR4 4523/4885DGAT1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.